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Background: Cardiovascular magnetic resonance (CMR) provides non-invasive and more accurate assessment of
right ventricular (RV) function in comparison to echocardiography. Recent study demonstrated that assessment of
RV function by echocardiography was an independent predictor for mortality in patients with interstitial lung
disease (ILD). The purpose of this study was to determine the prognostic significance of CMR derived RV ejection
fraction (RVEF) in ILD patients.
Methods: We enrolled 76 patients with ILD and 24 controls in the current study. By using 1.5 T CMR scanner
equipped with 32 channel cardiac coils, we performed steady-state free precession cine CMR to assess the RVEF. RV
systolic dysfunction (RVSD) was defined as RVEF ≤45.0% calculated by long axis slices. Pulmonary hypertension (PH)
was defined as mean pulmonary artery pressure (mPAP) of more than 25 mmHg at rest in the setting of pulmonary
capillary wedge pressure ≤15 mmHg.
Results: The median RVEF was 59.2% in controls (n = 24), 53.8% in ILD patients without PH (n = 42) and 43.1% in ILD
patients with PH (n = 13) (p < 0.001 by one-way ANOVA). During a mean follow-up of 386 days, 18 patients with RVSD
had 11 severe events (3 deaths, 3 right heart failure, 3 exacerbation of dyspnea requiring oxygen, 2 pneumonia requiring
hospitalization). In contrast, only 2 exacerbation of dyspnea requiring oxygen were observed in 58 patients without
RVSD. Multivariate Cox regression analysis showed that RVEF independently predicted future events, after adjusting for
age, sex and RVFAC by echocardiography (hazard ratio: 0.889, 95% confidence interval: 0.809 – 0.976, p = 0.014).
Conclusions: The current study demonstrated that RVSD in ILD patients can be clearly detected by cine CMR.
Importantly, low prevalence of PH (17%) indicated that population included many mild ILD patients. CMR derived RVEF
might be useful for the risk stratification and clinical management of ILD patients.
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Interstitial lung disease (ILD) is a life-threatening disease
characterized by progressive scarring of the lungs. Pul-
monary hypertension (PH) is frequently observed in ILD
patients and is closely associated with an increased risk
of death [1,2]. Hypoxic vasoconstriction and capillary
destruction play important roles in the progression of* Correspondence: shingo.m12226@gmail.com
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unless otherwise stated.PH [1]. PH is diagnosed as mean pulmonary arterial pres-
sure (mPAP) ≥ 25 mmHg at rest in the setting of normal
pulmonary capillary wedge pressure (PCWP) of 15 mmHg
or less by right heart catheterization (RHC) [3]. Although
invasive RHC is gold standard for the diagnosis of PH and
useful for the risk stratification, non-invasive methods that
can accurately predict the prognosis would be advanta-
geous for the clinical management for ILD patients.
A recent study demonstrated that echocardiography-
derived right ventricular (RV) functional parameters such
as RV systolic pressure (RVSP), tricuspid annular planeis is an Open Access article distributed under the terms of the Creative
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(RVFAC) were significant predictors of outcome in ILD
patients [4]. However, an important limitation of echocar-
diography is that the accuracy is substantially dependent
on operator’s skill. Furthermore, reproducibility of echo-
cardiography for the evaluation of RV function is limited
due to the complexity of anatomy.
Cardiovascular magnetic resonance (CMR) is accurate
and highly reproducible technique for the assessment of
RV function [5]. CMR derived RV end-systolic volume
(RVESV) has shown to be a strong prognostic factor in
patients with idiopathic pulmonary arterial hypertension
[6]. In addition, CMR derived RV function can assess
response to medical therapy in PH patients [7]. To the
best of our knowledge, no data is available regarding the
prognostic value of CMR derived RV ejection fraction
(RVEF) in ILD patients. Therefore, the aims of this study
were to assess RV function in ILD patients using cine
CMR and to investigate whether CMR derived RVEF
can predict future events.
Materials and methods
Study subjects
This study was approved by the institutional review
board, and all patients gave written informed consent.
Figure 1 summarizes the flow chart of patient enrollment.
According to the criteria developed by the American
Thoracic Society and European Respiratory Society [8,9],Figure 1 Flow chart of patient enrollment.eighty three ILD patients were prospectively enrolled from
June / 2009 to October / 2013. Diagnosis was performed
based on consensus of clinicians, pathologists and radiolo-
gists. Exclusion criteria were patients with cardiomyopathy
(hypertrophic cardiomyopathy, dilated cardiomyopathy
(DCM), arrhythmogenic right ventricular dysplasia), mod-
erate to severe valvular heart disease except for tricuspid
regurgitation, cardiac sarcoidosis, cardiac amyloidosis,
known history of coronary artery disease, pulmonary ar-
terial thromboembolism, any contraindication to CMR
(claustrophobia, after implantation of pacemaker etc.). We
excluded patients with severe mitral regurgitation (n = 4),
severe aortic stenosis (n = 2) detected by echocardiog-
raphy. In addition, chronic pulmonary arterial thrombo-
embolism (n = 1) patient was excluded. Seventy six
patients demonstrated interstitial abnormalities suggestive
of pulmonary fibrosis in the lung zones on chest computed
tomography images. 26 of 76 patients (34%) underwent
surgical lung biopsy and diagnosed histopathologically with
pulmonary fibrosis; usual interstitial pneumonia (UIP) pat-
tern, n = 8; fibrosing nonspecific interstitial pneumonia
(fNSIP) pattern, n = 11; non-classifiable fibrosis, n = 4;
hypersensitivity pneumonitis, n = 2; cryptogenic organizing
pneumonia, n = 1. Fifty five of 76 (72%) patients underwent
RHC to assess the presence or absence of PH. PH was de-
fined as mPAP of more than 25 mmHg at rest in the setting
of normal PCWP of 15 mmHg or less [3]. To compare the
CMR derived RV geometric and functional parameters, 24
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subjects with low-probability of coronary artery disease and
scanned as screening of coronary artery stenosis. They
didn’t have any typical chest pain, any history of heart dis-
ease nor lung disease. Non-contrast steady-state free pre-
cession (SSFP) whole heart coronary magnetic resonance
angiography (MRA) [10,11] and cine CMR were acquired,
and they didn’t show any coronary artery stenosis on whole
heart coronary MRA. We used cine CMR data from these
population as control.
Acquisition and analysis of CMR images
We acquired CMR images using a 1.5-T CMR system
equipped with 32-channel cardiac coils (Achieva,
Philips Healthcare, Best, The Netherlands). Vector-
electrocardiographic monitoring leads were positioned
on supine patients and then imaging started. Scout im-
ages were acquired in three orthogonal planes for car-
diac orientation. Short axis and horizontal long-axis
cine CMR images of the right ventricle were acquired
using a SSFP sequence (repetition time, 4.1 ms; echo
time, 1.7 ms; flip angle, 55°; field of view, 350 × 350 mm;
acquisition matrix, 128 × 128; slice thickness, 10 mm;
and 20 phases per cardiac cycle). To calculate the RV
end-diastolic volume (RVEDV) and RVESV, we used
long-axis cine CMR images and detected RV endocar-
dial border in all plains in all cardiac cycle. Then we
manually traced RV endcardial border with exclusion of
trabeculae both in end-systolic and end-diastolic phase.
Two observers used a workstation (Extend MR Work-
Space, Philips Healthcare) to analyze the cine CMR im-
ages. The observers were blinded to all of the patients’
clinical information, and the CMR images were reviewed
in random order. All measures of RV volume and mass
were indexed to body surface area. According to recent
guideline, right ventricular systolic dysfunction (RVSD)
was defined as RVEF ≤45% [12].
Echocardiography
Echocardiography was performed using commercially
available systems equipped with a 3.3-MHz transducer
(Vivid 7; GE Vingmed Ultrasound AS, Horten, Norway).
Right ventricular systolic pressure (RVSP) [13] and tri-
cuspid annular plane systolic excursion (TAPSE) [14]
and RV fractional area change (RVFAC) [15] were
evaluated.
Tricuspid annular plane systolic excursion (TAPSE)
The cursor was oriented to the junction of the tricus-
pid valve plane and the RV free wall in the apical
four-chamber view to measure TAPSE, which is an M-
mode-derived measurements of longitudinal displace-
ment of the annulus towards the apex during systole.
Right ventricular fractional area change (RVFAC).The RVFAC is expressed as percent change in the RV
chamber area from end-diastole to end-systole and is con-
sidered an index of RV systolic function. RV end-diastolic
area (RVEDA) and RV end-systolic area (RVESA) were
calculated from the apical four-chamber view. We calcu-
lated RVFAC from the following equation:
RVFAC %ð Þ ¼ RVEDA – RVESAð Þ = RVEDA  100
Right heart catheterization
In 55 of 76 (72%) patients, RHC was performed using a
standard thermodilution balloon-tipped pulmonary artery
catheter (Swan-Ganz ControlCath thermodilution cathe-
ters, Edwards Lifesciences Corp, Irvine, CA, USA) inserted
via an internal jugular or femoral vein. Thereafter, the pul-
monary artery catheter was floated under constant
pressure-wave monitoring into the pulmonary artery to
measure mean pulmonary artery pressure (mPAP), PCWP,
right ventricular pressure (RVP) and right atrial pressure
(RAP). Cardiac output was measured using the thermodi-
lution method or the Fick method.
Pulmonary function test
Pulmonary function tests (PFTs) were conducted in 70
of 76 (92%) patients. CHESTAC-8800, CHESTAC-33
(Chest MI Co., Tokyo, Japan) and Fudac-77 (Fukuda
Denshi, Tokyo) were used to measure vital capacity
(VC), forced expiratory volume in 1 second (FEV1), total
lung capacity (TLC) and diffusing capacity (DLCO)
using standard measurement techniques. The results
were expressed as percentage of predicted performance
using standard values [16] .
Statistical analysis
Data were statistically analyzed using SPSS software,
version 17.0 (SPSS, Inc, Chicago, IL, USA). Continuous
values are presented as means ± standard deviation (SD)
or medians with 1st quartile and 3rd quartile. Normality
was determined using the Shapiro-Wilk test. Normally
distributed values were compared using an unpaired t test
and non-normally distributed values were compared using
the Mann-Whitney U test. Spearman’s correlation coeffi-
cients were calculated to evaluate the relationship between
RVEF and mPAP. Intra-observer and inter-observer vari-
ability was assessed by using the Bland-Altman method
[17], with results reported as mean differences and 95%
limits of agreement. We calculated the cumulative inci-
dence of events according to presence or absence of RVSD
using the Kaplan-Meier method and compared the two
curves with a log-rank test. We used Cox proportional
hazards models to estimate hazard ratio (HR) for cardio-
vascular events and 95% confidence interval (CI). A P
value < 0.05 was considered significant.
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Patient characteristics
Characteristics of all patients are presented in Table 1.
The average age was 70 ± 7 years old, and 70% of the pa-
tients were male. The Medical Research Council (MRC)
score was 2.1 ± 1.0, median BNP was 24.2 pg/ml (normal
range of BNP is ≦18.4 pg/ml in our hospital) and the 6-
minute walk distance was 428 ± 78 m. Based on the
CMR data, the ILD patients were divided into a group
with RVSD (RVEF ≤45%, n = 18) and a group without
RVSD (RVEF > 45%, n = 58). Rate of male, MRC dyspnea
score were significantly higher in RVSD group compared
with those without RVSD. Other parameters obtained
from blood test and echocardiographic parameters were
not significantly different between the two groups.Hemodynamic parameters and pulmonary function test
Table 2 summarizes the results of hemodynamic param-
eters and pulmonary function test. PH by RHC was
observed in 13 of 55 (24%) patients in this cohort. The
mPAP and presence of PH were significantly higher in
patients with RVSD in comparison to those without.
The results of pulmonary function test did not signifi-
cantly differ between two groups.Table 1 Characteristics of patients
ILD without RVSD n = 58
Age 70 ± 7
Male sex 37 (64%)
MRC dyspnea scale 1.9 ± 0.8
BMI, kg/m2 23.8 ± 4.2
Systolic BP, mmHg 131 ± 15
Diastolic BP, mmHg 78 ± 9
Heart rate, bpm 71 ± 11
Blood testing
BNP, pg/ml 22.2 (1.7–42.7)
Creatinine, mg/dl 0.82 (0.68–0.96)
KL-6, U/ml 772 (428-1066)
LDH, IU/l 234 ± 40
CRP, mg/dl 0.15 (0.01-0.29)
Pulmonary function test ILD without RVSD n = 14
FVC, % predicted 89.4 (73.2-105.6)
FEV1, % predicted 79.7 ± 15.0
DLCO, % predicted 70.7 ± 17.5
Values are presented as mean ± standard deviation (SD) or median (1st quartile and
RV dysfunction was defined as RVEF ≤45% evaluated by cine CMR.
*P value represents significance of difference between ILD patient with RVSD and t
BMI: body mass index; BNP: brain natriuretic peptide; BP: blood pressure; CRP: C-rea
FEV: forced expiratory volume; FVC: forced vital capacity; ILD: interstitial lung diseas
right ventricular systolic dysfunction.RV functional and geometric indices assessed by CMR
Figure 2 shows a representative ILD case and control
subject in this study. The right ventricle was substan-
tially larger in the ILD patient compared with the con-
trol subject. Figure 3 illustrates the comparison of RV
functional and geometric parameters assessed by cine
CMR. Significant differences were found between con-
trol subjects and ILD patients without PH in RVEDVI,
RVESVI and RVEF. In addition, RVEF showed signifi-
cant differences between ILD patients with and with-
out PH. The median RVEF was 59.2% in controls (n =
24), 53.8% in ILD patients without PH (n = 42) and
43.1% in ILD patients with PH (n = 13) (p < 0.001 by
one-way ANOVA). Spearman’s correlation coefficient
showed that RVEF was negatively correlated with
mPAP (r = -0.32, p = 0.017).
Prognostic value of right ventricular ejection fraction by
CMR in patients with ILD
During a mean follow-up of 386 days, 18 patients with
RVSD experienced 11 severe events (3 deaths, 3 right
heart failure, 3 exacerbation of dyspnea requiring oxygen,
2 pneumonia requiring hospitalization). In contrast, only 2
exacerbation of dyspnea requiring oxygen were observed
in 58 patients without RVSD. Figure 4 shows Kaplan-ILD with RVSD n = 18 *P-value
71 ± 4 0.76
16 (89%) 0.043
2.7 ± 1.1 0.006
22.1 ± 1.9 0.08
135 ± 19 0.59
77 ± 10 0.66




211 ± 50 0.62
0.12 (0.01-0.23) 0.66
ILD with RVSD n = 56 *P-value
85.8 (82.6-89.0) 0.71
86.2 ± 11.9 0.89
68.1 ± 25.8 0.06
3rd quartile).
hose without.
ctive protein; DLCO: diffusing capacity of the lungs for carbon monoxide;
e; LDH: lactic acid dehydrogenase; MRC: Medical Research Council; RVSD:
Table 2 Echocardiographic parameters and right heart catheterization
Echocardiography ILD without RVSD n = 58 ILD with RVSD n = 18 *P-value
TAPSE, mm 20.4 ± 3.5 19.7 ± 2.9 0.64
RVSP, mmHg 31.9 (18.9-44.9) 31.9 (24.4-39.4) 0.64
RVFAC, % 39.4 ± 9.1 37.7 ± 10.4 0.49
LVEF, % 63.6 ± 8.4 65.6 ± 5.8 0.54
LVDd, mm 41.6 (38.6-44.6) 42.5 (38.5-46.5) 0.086
Right heart catheterization ILD without RVSD n = 16 ILD with RVSD n = 39 *P-value
RAP, mmHg 4.5 ± 3.4 6.2 ± 4.1 0.94
mPAP, mmHg 19.0 (15.5-22.5) 21.5 (17.0-26.0) 0.005
PCWP, mmHg 8.2 ± 3.7 8.5 ± 3.8 0.21
SVR, dyne·sec·cm-5 324 (210-438) 315 (223-407) 0.41
PVR, dyne·sec·cm-5 152 (85-219) 147 (36-258) 0.060
Cardiac Index, L/min/m2 2.8 (2.3-3.3) 2.8 (2.3-3.3) 0.95
Values are presented as mean ± standard deviation (SD) or median (1st quartile and 3rd quartile).
RV dysfunction was defined as RVEF ≤45% evaluated by cine CMR.
*P value represents significance of difference between ILD patient with RVSD and those without.
ILD: interstitial lung disease; LVDd: left ventricular dimension at end of diastole; LVEF: left ventricular ejection fraction; mPAP: mean pulmonary arterial pressure;
PCWP: pulmonary capillary wedge pressure; PVR: pulmonary vascular resistance; RAP: right atrial pressure; RVFAC: right ventricular fractional area change; RVSD:
right ventricular systolic dysfunction; RVSP: right ventricular systolic pressure; SVR: systemic vascular resistance; TAPSE: tricuspid annular plane systolic excursion.
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presence or absence of RVSD. A significant difference was
observed between patients with and without RVSD
(p < 0.001 by log-rank test). Table 3 summarizes the result
of the Cox proportional hazards analysis for future events.
In univariate analysis, RVFAC (HR: 0.916, 95% CI: 0.853 –(A)
Figure 2 Comparison of cine CMR between a patient with ILD and a c
diffuse fibrosis mainly located in the lower lungs in a patient with interstitial lu
decreased RV function in an ILD patient (B: end-diastolic and C: end systolic im
the ILD patient (D: end-diastolic and E: end systolic image). ILD: interstitial lun0.985, p = 0.018) and CMR derived RVEF (HR: 0.889, 95%
CI: 0.809 – 0.976, p = 0.014) were significant predictors of
future events. In multivariate Cox regression analysis,
CMR derived RVEF (HR: 0.897, 95% CI: 0.810 – 0.992,





Patient with interstitial lung disease
Control subject
(C)
ontrol subject. (A): Chest computed tomography demonstrated
ng disease (ILD). Cine CMR showed an enlarged right ventricle (RV) and
age). In the control subject, the RV size was substantially smaller than in
g disease; CMR: cardiovascular magnetic resonance; RV: right ventricle.
Figure 3 CMR derived RV functional and geometric indices. Comparison of CMR derived RV volume, RVEF between the 3 groups (control,
ILD patients without PH and ILD patients with PH). *Significantly different from controls, † Significantly different from ILD patients without PH.
ILD: interstitial lung disease; RV: right ventricle; CMR: cardiovascular magnetic resonance; EDVI: end-diastolic volume index; ESVI end-systolic
volume index; RVEF: right ventricular ejection fraction.
Figure 4 Kaplan Meyer event-free survival curve. RV dysfunction
was defined as RVEF ≤45% evaluated by cine CMR. RV: right ventricle;
EF: ejection fraction; CMR: cardiovascular magnetic resonance.
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measurements
Analysis of both the intra-observer and inter-observer
variability showed high levels of agreement for the meas-
urement of RVEF. The mean difference (95% limits of
agreement) for the intra-observer study was 1.1% (−5.0,
7.2), whereas for inter-observer study this was 1.3%
(−5.7, 8.3).
Discussion
This study demonstrated that RV functional and geo-
metric changes can be measured by cine CMR in pa-
tients with ILD with high reproducibility. Importantly,
the study subjects included many mild ILD patients with
low-prevalence of PH. RV systolic function was signifi-
cantly reduced in ILD patient both with and without PH
as compared with control subjects. Furthermore, multi-
variate Cox regression hazards analysis revealed that
CMR derived RVEF was strong predictor of future
events in ILD patients.
Table 3 Cox Proportional Hazards Analysis for Future Events in Patients with ILD
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Patients’ characteristics
Age, year 0.987 0.932 – 1.046 0.66 0.978 0.913 – 1.048 0.53
Male, yes 1.382 0.298 – 6.401 0.68 1.015 0.190 – 5.420 0.99
MRC dyspnea scale 1.660 0.938 – 2.937 0.082 Not selected
BMI, kg/m2 1.021 0.859 – 1.213 0.82 Not selected
Systolic BP, mmHg 1.018 0.981 – 1.056 0.35 Not selected
Diastolic BP, mmHg 1.021 0.970 – 1.074 0.43 Not selected
Heart rate, bpm 1.011 0.978 – 1.046 0.51 Not selected
Blood testing
BNP, pg/ml 1.000 0.997 – 1.002 0.88 Not selected
Creatinine, mg/dl 4.179 0.505 – 34.60 0.19 Not selected
KL-6, U/ml 1.000 0.999 – 1.001 0.40 Not selected
LDH, IU/l 1.003 0.991 – 1.015 0.63 Not selected
CRP, mg/dl 0.827 0.430 – 1.591 0.57 Not selected
Pulmonary function test
FVC, % predicted 0.996 0.967 – 1.025 0.77 Not selected
FEV1, % predicted 0.958 0.915 – 1.003 0.065 Not selected
DLCO, % predicted 0.965 0.930 – 1.002 0.064 Not selected
6 min walk distance, m 0.995 0.985 – 1.005 0.35 Not selected
Right heart catheterization
mPAP, mmHg 1.003 0.956 – 1.051 0.913 Not selected
PCWP, mmHg 1.001 0.843 – 1.189 0.992 Not selected
Echocardiography
TAPSE, mm 0.863 0.727 – 1.024 0.092 Not selected
RVFAC, % 0.916 0.853 – 0.985 0.018 0.938 0.873 – 1.007 0.078
Cine CMR parameters
CMR derived RVEF, % 0.889 0.809 – 0.976 0.014 0.897 0.810 – 0.992 0.035
BMI: body mass index; BNP: brain natriuretic peptide; BP: blood pressure; CRP: C-reactive protein; CMR: cardiovascular magnetic resonance; DLCO: diffusing capacity
of the lungs for carbon monoxide, FEV: forced expiratory volume; FVC: forced vital capacity; ILD: interstitial lung disease; LDH: lactic acid dehydrogenase; MRC:
Medical Research Council; mPAP: mean pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; RVEF: right ventricular ejection fraction; RVFAC:
right ventricular fractional area change; TAPSE: tricuspid annular plane systolic excursion.
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diseases
Recent studies demonstrated clinical significance of as-
sessment of RV function by CMR. Gulati, A. et al. stud-
ied 250 DCM patients and showed that RVSD (defined
as RVEF ≤45% on cine CMR) is a powerful predictor of
transplant-free survival and adverse heart failure out-
come in DCM patients [18]. Another data by Swift, A. J.
et al. revealed prognostic value of CMR measure in 80
patients with idiopathic pulmonary hypertension. Right
ventricular volume by cine CMR after corrected by age,
sex and body surface area strongly predicted mortality
[6]. Same group showed the excellent diagnostic accur-
acy of CMR for the detection of PH by RHC insuspected patients [19]. RV mass index showed stron-
gest correlation with mPAP (r = 0.78 by Pearson’s cor-
relation coefficient) and highest diagnostic accuracy
with area under the receiver operating characteristics
curve of 0.91. In addition, Peacock, A. J. et al. evaluated
utility of CMR for monitoring the efficacy of medical
treatment in 91 patients with PH, and showed that
CMR derived measures from left and right side of the
heart reflected change of functional change and survival
in PH patients [7]. To the best of our knowledge, this is
the first investigation to evaluate the CMR derived
RVEF in ILD patients. Cine CMR clearly demonstrated
RV dysfunction even in mild ILD patients with low-
prevalence of PH.
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in patients with ILD
One of the important mechanism for RV remodeling
and dysfunction in patients with ILD is increased after-
load caused by hypoxic pulmonary vasoconstriction [3].
We found a significant difference in RVEF between ILD
patients with and without PH (53.8% vs 43.1%, respect-
ively, p < 0.001). In addition, there was a negative correl-
ation between mPAP and RVEF in ILD patients (r = -0.32,
p = 0.017). These results indicated that elevation of after-
load could be one of the main mechanism of RVSD in
ILD patients. Interestingly, we found a significant differ-
ence in RVEF between ILD patients without PH and con-
trol subjects. In ILD patients without PH, the mPAP was
18 ± 4 mmHg, which is slightly higher than normal level
of 14.7 ± 4.0 mmHg (mean value in subjects) [20] and less
than 20 mmHg (upper limit of normal) [21]. However,
RVEF was significantly decreased in ILD patients without
PH as compared with controls (53.8% vs 59.2%, respect-
ively, p < 0.001). Similar results were reported in a previ-
ous study of COPD patients conducted by Hilde, J. M. et al.
[22]. We assumed that an additive mechanism, except
for the elevation of mPAP, might be present for RV
dysfunction in the early stage of ILD, such as systemic
inflammation or endothelial dysfunction [23].
Prognostic value of RVEF evaluated by cine CMR in
patients with ILD
A recent study showed that increased RV size and RV
dysfunction measured by echocardiography and higher
pulmonary vascular resistance measured by RHC predict
mortality in patients with idiopathic pulmonary fibrosis
evaluated for lung transplantation [4]. In the current
study, multivariate Cox proportional hazards analysis
demonstrated that only CMR derived RVEF (HR: 0.897,
95% CI: 0.810 – 0.992, p = 0.035) was an independent
predictor of future event, whereas echocardiographic
parameter such as TAPSE and RVFAC were not signifi-
cant. Our data suggest that CMR can provide more accur-
ate information regarding RV function and prognostic
value than echocardiography. Although the CMR is at-
tractive non-invasive modality, we cannot neglect the clin-
ical utility of RHC at least in the initial diagnosis of PH. In
addition, RHC is also important for excluding underlying
heart failure such as heart failure with preserved ejection
fraction (HFpEF). In our data, DLCO was not a significant
predictor of prognosis, however, we found trend down-
wards between DLCO and right ventricular systolic dys-
function (RVSD) on CMR (DLCO: 70.7 ± 17.5 in ILD
without RVSD vs 68.1 ± 25.8 in ILD with RVSD, p = 0.06).
In addition, when we compared echocardiographic RV
measures, TAPSE didn’t come out significant (p = 0.092),
but RVFAC did (p = 0.018) as a prognostic factor in uni-
variate Cox regression analysis (Table 3). In a study byAnavekar, NS et al., RVFAC was well correlated CMR
derived EF (r = 0.80, P < 0.001), however TAPSE was not
correlated (r = 0.17, P = 0.30) [24]. These results could be
explained by the fact that RVFAC is more accurate RV
functional measure than TAPSE.
Study limitations
First, this study was a single-center study and included a
relatively limited number of patients. Again, important
limitation of this study was that the study cohort con-
sisted of mainly mild ILD with low prevalence of PH.
The findings of this study was not necessarily true for
the patients with severe form of ILD. Therefore, large
scale study is necessary to clarify if CMR has prognostic
value in moderate to severe ILD with high prevalence of
PH. Second, the mean follow-up duration was about one
year. Longer clinical follow-up is required to investigate
the long-term prognostic value of RV function assessed
by CMR in patients with ILD. Third, although RVEF cal-
culated by cine CMR is a non-invasive and useful index,
CMR is problematic for patients with claustrophobia,
and only recently becoming possible in patients with
pacemakers or cardiovascular defibrillators.
Conclusion
The current study demonstrated that CMR derived
RVEF could predict future severe events in ILD pa-
tients. RV functional assessment by cine CMR might
be useful for risk stratification and clinical manage-
ment in ILD patients.
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